Shopping Cart
- Remove All
- Your shopping cart is currently empty
Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $59 | In Stock | |
2 mg | $84 | In Stock | |
5 mg | $123 | In Stock | |
10 mg | $197 | In Stock | |
25 mg | $357 | In Stock | |
50 mg | $597 | In Stock | |
100 mg | $852 | In Stock | |
500 mg | $1,730 | In Stock |
Description | Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production. |
Targets&IC50 | TPO receptor:3.3 nM (EC50) |
In vivo | Avatrombopag is treatment of thrombocytopenia in patients with CLD who are scheduled to undergo a procedure[1]. |
Alias | YM477, E5501, AKR-501 |
Molecular Weight | 649.65 |
Formula | C29H34Cl2N6O3S2 |
Cas No. | 570406-98-3 |
Smiles | OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1 |
Relative Density. | 1.440 g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO: < 1 mg/mL (insoluble) |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.